Drugs / ATR-258
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06432673 | Apr → May 2024 | type 2 diabetes mellitus | Atrogi AB | Completed | No outcome recorded |
| Phase 1 | NCT05409924 | Apr 2022 → Oct 2023 | type 2 diabetes mellitus | Atrogi AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07421024 | Feb → Dec 2026 expected | morbid obesity | Morten Hostrup, PhD | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-24 | Atrogi AB | Results Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease atrogi.com ↗
This paper highlights Atrogi’s first-in-class oral β2-adrenergic receptor agonist, ATR-258, which precisely activates skeletal muscle metabolism through novel GRK2-biased signaling. |
| 2024-03-14 | Atrogi AB | Results Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes atrogi.com ↗
Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Atrogi AB | Atrogi announces first subjects dosed in human trial for lead candidate ATR-258 atrogi.com ↗ |
| 2025-06-24 | Atrogi AB | Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease atrogi.com ↗ |
| 2024-03-14 | Atrogi AB | Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes atrogi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATR-258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05409924 ↗ |
| Action | Activate | “GRK-selective long-acting β2-agonist ATR-258” NCT07421024 ↗ |
| Route | Oral | “an oral capsule formulation” NCT06432673 ↗ |